A Phase 3 interventional study of Ixekizumab and Placebo in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 69 sites in 13 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-09-27.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 3, and was the 13th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 17th largest by enrollment, is one of 2 that started in 2017, is one of 15 in phase 3, and was the 19th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have received other therapies within the specified time frames prior to screening (see below):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.
Drug: Ixekizumab
Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.
Drug: Placebo
Etanercept given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period. Participants will only be randomized to etanercept in countries where it is approved for severe pediatric psoriasis treatment.
Drug: Etanercept
Administered SC
Also known as: LY2439821
Administered SC
Administered SC
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab)
PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total body surface area (BSA) affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
Time frame: Week 12
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Placebo and Ixekizumab)
Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.
Time frame: Week 12
Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)
PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%.Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
Time frame: Week 12
Percentage of Participants With a sPGA (0)
Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis. An sPGA assessed as 0 represents a clinically important endpoint indicating complete resolution of plaque psoriasis.
Time frame: Week 12
Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)
PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
Time frame: Week 12
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
Time frame: Week 4
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1)
Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.
Time frame: Week 4
Percentage of Participants With an Improvement of ≥4 in Those Who Had a Baseline Itch Numeric Rating Scale (NRS) Score of ≥4
Itch Numeric Rating Scale (NRS): is a single-item, patient-reported outcome (PRO) measure designed to capture the overall severity of a participant's itching due to his/her psoriasis by having the patient circle the integer that describes the worst level of itching in the past 24 hours on an 11-point NRS anchored at 0 representing "no itching" and 10 representing "worst itch imaginable.
Time frame: Week 12
Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI)/Dermatology Life Quality Index (DLQI) (0/1)
DLQI is a validated, dermatology-specific, patient reported measure that evaluates participant's health-related quality of life. It consists of 10 items that are grouped in 6 domains: symptoms \& feelings, daily activities, leisure, work \& school , personal relationships, \& treatment. The recall period of this scale is over the "last week." Response categories and corresponding scores are: Very much = 3, A lot = 2, A little = 1, Not at all = 0, Not relevant = 0. A DLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment). CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. A CDLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment).
Time frame: Week 12
Change From Baseline on the Nail Psoriasis Severity Index (NAPSI)
NAPSI is a numeric, reproducible, objective tool for evaluation of nail psoriasis. This scale was used to evaluate the severity of nail bed psoriasis \& nail matrix psoriasis by area of involvement in the nail unit. Both fingernail \& toenail involvement were assessed.The nail is divided with imaginary horizontal \& longitudinal lines into quadrants. Each nail is given a score for nail bed psoriasis (0 to 4) \& nail matrix psoriasis (0 to 4), depending on the presence (score of 1) or absence (score of 0) of any of the features of nail bed \& nail matrix psoriasis in each quadrant: 0 = None 1. = present in one quadrant of nail 2. = present in two quadrants of nail 3. = present in three quadrants of nail 4. = present in four quadrants of nail NAPSI score of a nail is the sum of scores in nail bed \& nail matrix from each quadrant (maximum of 8). Each nail is evaluated, \& the sum of all the fingernails and toenails is the total NAPSI score ranging from 0 to 160 (No to Severe nail Psoriasis)
Time frame: Baseline, Week 12
Change From Baseline on the Psoriasis Scalp Severity Index (PSSI)
The scalp was assessed for erythema (redness), induration (hardness), and desquamation (shedding of skin) and percentage of area affected as follows: Erythema, Induration and Desquamation: 0 = Absent 1. = Slight 2. = Moderate 3. = Severe 4. = Severest Possible Percent of Scalp Involved: 1. = \<10% 2. = 10% - 29% 3. = 30% - 49% 4. = 50% - 69% 5. = 70% - 89% 6. = 90% - 100% The PSSI score is a composite score derived from the sum of the scores for erythema, induration and desquamation multiplied by the score for the extent of scalp area involved (percent of scalp involved). The range is 0 (no psoriasis) to 72 (Most severe Disease). LSMean was calculated using treatment, region, baseline sPGA score, baseline weight category, baseline value, visit, treatment-by-visit, and baseline-by-visit interactions as fixed factors.
Time frame: Baseline, Week 12
Change From Baseline on the Palmoplantar Psoriasis Severity Index (PPASI)
PPASI was used if the participant has palmoplantar psoriasis at baseline. Both the palms \& soles on each hand \& foot was assessed for erythema, induration, desquamation \& percentage of area affected as follows: Erythema (E), Induration (I), \& Desquamation (D):0 = None, 1 = Slight, 2 = Moderate, 3 = Severe, 4 = Very Severe Percent of Palm and Sole Area Covered: 0 = None, 1 = \<10%, 2 = 10% - 29%, 3 = 30% - 49%, 4 = 50% - 69%, 5 = 70% - 89%, 6 = 90% - 100% PPASI score is a composite score derived from the sum scores for E, I, \& D multiplied by a score for the extent of palm \& sole area involvement. The range is 0 (no psoriasis) to 72 (most severe disease).
Time frame: Baseline, Week 12
Number of Participants With Anti-Ixekizumab Antibodies
A treatment emergent - antidrug antibody (TE-ADA) positive participant were defined as: 1. a participant with a \>= 4-fold increase over a positive baseline antibody titer; or 2. for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10.
Time frame: Baseline through Week 48
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss).
Time frame: Week 12
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Etanercept Approved Countries)
PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
Time frame: Week 12
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Etanercept Approved Countries)
Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.
Time frame: Week 12
Double-Blind Treatment Period (Week 0 to Week 12), Open-Label Maintenance Period (Week 12 to Week 60), Extension Period (Week 60 to Week 108) followed by post-treatment follow-up period occurring from last treatment visit (week 108), or Early Termination Visit (ETV) for up to 24 weeks following that visit. Etanercept (ETN) is reference control group occurred only in Etanercept approved countries.
| Milestone | PBO (Double-Blinded Treatment Period) | IXEQ4W (Double-Blinded Treatment Period) | ETN (Double-Blinded Treatment Period) | PBO/IXEQ4W (Maintenance Period) | IXEQ4W/IXEQ4W (Maintenance Period) | ETN/IXEQ4W (Maintenance Period) | PBO/IXEQ4W/IXEQ4W (Extension Period) | IXEQ4W/IXEQ4W/IXEQ4W (Extension Period) | ETN/IXEQ4W/IXEQ4W (Extension Period) | PBO (Randomized Withdrawal Period) | IXEQ4W (Randomized Withdrawal Period) | IXEQ4W_Re-Treatment (Randomized Withdrawal) Period | PBO (Post-Treatment Follow-Up) | IXEQ4W (Post-Treatment Follow-Up) | ETN (Post-Treatment Follow-Up) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 56 | 115 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants in etanercept approved countries | 19 | 38 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 54 | 114 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PBO (Double-Blinded Treatment Period) | IXEQ4W (Double-Blinded Treatment Period) | ETN (Double-Blinded Treatment Period) | PBO/IXEQ4W (Maintenance Period) | IXEQ4W/IXEQ4W (Maintenance Period) | ETN/IXEQ4W (Maintenance Period) | PBO/IXEQ4W/IXEQ4W (Extension Period) | IXEQ4W/IXEQ4W/IXEQ4W (Extension Period) | ETN/IXEQ4W/IXEQ4W (Extension Period) | PBO (Randomized Withdrawal Period) | IXEQ4W (Randomized Withdrawal Period) | IXEQ4W_Re-Treatment (Randomized Withdrawal) Period | PBO (Post-Treatment Follow-Up) | IXEQ4W (Post-Treatment Follow-Up) | ETN (Post-Treatment Follow-Up) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 53 | 113 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 49 | 109 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant moved to another city | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PBO (Double-Blinded Treatment Period) | IXEQ4W (Double-Blinded Treatment Period) | ETN (Double-Blinded Treatment Period) | PBO/IXEQ4W (Maintenance Period) | IXEQ4W/IXEQ4W (Maintenance Period) | ETN/IXEQ4W (Maintenance Period) | PBO/IXEQ4W/IXEQ4W (Extension Period) | IXEQ4W/IXEQ4W/IXEQ4W (Extension Period) | ETN/IXEQ4W/IXEQ4W (Extension Period) | PBO (Randomized Withdrawal Period) | IXEQ4W (Randomized Withdrawal Period) | IXEQ4W_Re-Treatment (Randomized Withdrawal) Period | PBO (Post-Treatment Follow-Up) | IXEQ4W (Post-Treatment Follow-Up) | ETN (Post-Treatment Follow-Up) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 34 | 68 | 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 31 | 62 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 6 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PBO (Double-Blinded Treatment Period) | IXEQ4W (Double-Blinded Treatment Period) | ETN (Double-Blinded Treatment Period) | PBO/IXEQ4W (Maintenance Period) | IXEQ4W/IXEQ4W (Maintenance Period) | ETN/IXEQ4W (Maintenance Period) | PBO/IXEQ4W/IXEQ4W (Extension Period) | IXEQ4W/IXEQ4W/IXEQ4W (Extension Period) | ETN/IXEQ4W/IXEQ4W (Extension Period) | PBO (Randomized Withdrawal Period) | IXEQ4W (Randomized Withdrawal Period) | IXEQ4W_Re-Treatment (Randomized Withdrawal) Period | PBO (Post-Treatment Follow-Up) | IXEQ4W (Post-Treatment Follow-Up) | ETN (Post-Treatment Follow-Up) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 34 | 33 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 32 | 30 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | PBO (Double-Blinded Treatment Period) | IXEQ4W (Double-Blinded Treatment Period) | ETN (Double-Blinded Treatment Period) | PBO/IXEQ4W (Maintenance Period) | IXEQ4W/IXEQ4W (Maintenance Period) | ETN/IXEQ4W (Maintenance Period) | PBO/IXEQ4W/IXEQ4W (Extension Period) | IXEQ4W/IXEQ4W/IXEQ4W (Extension Period) | ETN/IXEQ4W/IXEQ4W (Extension Period) | PBO (Randomized Withdrawal Period) | IXEQ4W (Randomized Withdrawal Period) | IXEQ4W_Re-Treatment (Randomized Withdrawal) Period | PBO (Post-Treatment Follow-Up) | IXEQ4W (Post-Treatment Follow-Up) | ETN (Post-Treatment Follow-Up) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 166 | 2 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 139 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Participant moved to another city | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Site terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 |
| Withdrew: Other-determined by investigator | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total body surface area (BSA) affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
| percentage of participants | Placebo | Ixekizumab |
|---|---|---|
| Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab) | 25 | 88.7 |
Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.
| percentage of participants | Placebo | Ixekizumab |
|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Placebo and Ixekizumab) | 10.7 | 80.9 |
PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%.Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
| percentage of participants | Placebo | Ixekizumab |
|---|---|---|
| Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) | 5.4 | 78.3 |
Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis. An sPGA assessed as 0 represents a clinically important endpoint indicating complete resolution of plaque psoriasis.
| percentage of participants | Placebo | Ixekizumab |
|---|---|---|
| Percentage of Participants With a sPGA (0) | 1.8 | 52.2 |
PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
| percentage of participants | Placebo | Ixekizumab |
|---|---|---|
| Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) | 1.8 | 49.6 |
PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
| percentage of participants | Placebo | Ixekizumab |
|---|---|---|
| Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) | 8.9 | 53.9 |
Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.
| percentage of participants | Placebo | Ixekizumab |
|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) | 7.1 | 47.8 |
Itch Numeric Rating Scale (NRS): is a single-item, patient-reported outcome (PRO) measure designed to capture the overall severity of a participant's itching due to his/her psoriasis by having the patient circle the integer that describes the worst level of itching in the past 24 hours on an 11-point NRS anchored at 0 representing "no itching" and 10 representing "worst itch imaginable.
| percentage of participants | Placebo | Ixekizumab |
|---|---|---|
| Percentage of Participants With an Improvement of ≥4 in Those Who Had a Baseline Itch Numeric Rating Scale (NRS) Score of ≥4 | 20.0 | 71.1 |
DLQI is a validated, dermatology-specific, patient reported measure that evaluates participant's health-related quality of life. It consists of 10 items that are grouped in 6 domains: symptoms \& feelings, daily activities, leisure, work \& school , personal relationships, \& treatment. The recall period of this scale is over the "last week." Response categories and corresponding scores are: Very much = 3, A lot = 2, A little = 1, Not at all = 0, Not relevant = 0. A DLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment). CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. A CDLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment).
| percentage of participants | Placebo | Ixekizumab |
|---|---|---|
| Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI)/Dermatology Life Quality Index (DLQI) (0/1) | 23.2 | 64.3 |
NAPSI is a numeric, reproducible, objective tool for evaluation of nail psoriasis. This scale was used to evaluate the severity of nail bed psoriasis \& nail matrix psoriasis by area of involvement in the nail unit. Both fingernail \& toenail involvement were assessed.The nail is divided with imaginary horizontal \& longitudinal lines into quadrants. Each nail is given a score for nail bed psoriasis (0 to 4) \& nail matrix psoriasis (0 to 4), depending on the presence (score of 1) or absence (score of 0) of any of the features of nail bed \& nail matrix psoriasis in each quadrant: 0 = None 1. = present in one quadrant of nail 2. = present in two quadrants of nail 3. = present in three quadrants of nail 4. = present in four quadrants of nail NAPSI score of a nail is the sum of scores in nail bed \& nail matrix from each quadrant (maximum of 8). Each nail is evaluated, \& the sum of all the fingernails and toenails is the total NAPSI score ranging from 0 to 160 (No to Severe nail Psoriasis)
| score on a scale | Placebo | Ixekizumab |
|---|---|---|
| Change From Baseline on the Nail Psoriasis Severity Index (NAPSI) | 0.17 ± 5.331 | -16.87 ± 3.110 |
The scalp was assessed for erythema (redness), induration (hardness), and desquamation (shedding of skin) and percentage of area affected as follows: Erythema, Induration and Desquamation: 0 = Absent 1. = Slight 2. = Moderate 3. = Severe 4. = Severest Possible Percent of Scalp Involved: 1. = \<10% 2. = 10% - 29% 3. = 30% - 49% 4. = 50% - 69% 5. = 70% - 89% 6. = 90% - 100% The PSSI score is a composite score derived from the sum of the scores for erythema, induration and desquamation multiplied by the score for the extent of scalp area involved (percent of scalp involved). The range is 0 (no psoriasis) to 72 (Most severe Disease). LSMean was calculated using treatment, region, baseline sPGA score, baseline weight category, baseline value, visit, treatment-by-visit, and baseline-by-visit interactions as fixed factors.
| score on a scale | Placebo | Ixekizumab |
|---|---|---|
| Change From Baseline on the Psoriasis Scalp Severity Index (PSSI) | -12.28 ± 2.572 | -27.64 ± 2.320 |
PPASI was used if the participant has palmoplantar psoriasis at baseline. Both the palms \& soles on each hand \& foot was assessed for erythema, induration, desquamation \& percentage of area affected as follows: Erythema (E), Induration (I), \& Desquamation (D):0 = None, 1 = Slight, 2 = Moderate, 3 = Severe, 4 = Very Severe Percent of Palm and Sole Area Covered: 0 = None, 1 = \<10%, 2 = 10% - 29%, 3 = 30% - 49%, 4 = 50% - 69%, 5 = 70% - 89%, 6 = 90% - 100% PPASI score is a composite score derived from the sum scores for E, I, \& D multiplied by a score for the extent of palm \& sole area involvement. The range is 0 (no psoriasis) to 72 (most severe disease).
| score on a scale | Placebo | Ixekizumab |
|---|---|---|
| Change From Baseline on the Palmoplantar Psoriasis Severity Index (PPASI) | 6.89 ± 3.37 | -5.11 ± 2.148 |
A treatment emergent - antidrug antibody (TE-ADA) positive participant were defined as: 1. a participant with a \>= 4-fold increase over a positive baseline antibody titer; or 2. for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10.
| participants | Ixekizumab (Maintenance Period) |
|---|---|
| Number of Participants With Anti-Ixekizumab Antibodies | 56 |
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss).
| microgram per milliliter (μg/mL) | Ixekizumab |
|---|---|
| Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss) | 3.03 ± 106 |
PASI combines assessments of the extent of body surface involvement in 4 regions (head \& neck(h), trunk(t), arms(u), legs(l)) \& severity of scaling (S), redness (R), \& plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total BSA affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = \>0% to \<10%, 2 = 10% to \<30%, 3 = 30% to \<50%, 4 = 50% to \<70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease).
| percentage of participants | Placebo | Ixekizumab | Open-Label Etanercept |
|---|---|---|---|
| Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Etanercept Approved Countries) | 26.3 | 84.2 | 63.3 |
Static Physician Global Assessment (sPGA): The physician's global assessment of the Participant's psoriasis lesions at a given time point. Plaques are assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity is given using the anchors of clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of plaque psoriasis.
| percentage of participants | Placebo | Ixekizumab | Open-Label Etanercept |
|---|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) (Etanercept Approved Countries) | 5.3 | 76.3 | 53.3 |
Collected over Up to 132 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PBO (Double-Blinded Treatment Period) | 0/56 (0%) | 0/56 (0%) | 14/56 (25%) |
| IXEQ4W (Double-Blinded Treatment Period) | 0/115 (0%) | 1/115 (0.9%) | 49/115 (42.6%) |
| ETN (Double-Blinded Treatment Period) | 0/30 (0%) | 1/30 (3.3%) | 7/30 (23.3%) |
| PBO/IXEQ4W (Maintenance Period) | 0/53 (0%) | 3/53 (5.7%) | 33/53 (62.3%) |
| IXEQ4W/IXEQ4W (Maintenance Period) | 0/113 (0%) | 7/113 (6.2%) | 76/113 (67.3%) |
| ETN/IXEQ4W (Maintenance Period) | 0/28 (0%) | 1/28 (3.6%) | 18/28 (64.3%) |
| PBO/IXEQ4W/IXEQ4W (Extension Period) | 0/34 (0%) | 0/34 (0%) | 20/34 (58.8%) |
| IXEQ4W/IXEQ4W/IXEQ4W (Extension Period) | 0/68 (0%) | 2/68 (2.9%) | 43/68 (63.2%) |
| ETN/IXEQ4W/IXEQ4W (Extension Period) | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| PBO (Randomized Withdrawal Period) | 0/33 (0%) | 0/33 (0%) | 15/33 (45.5%) |
| IXEQ4W (Randomized Withdrawal Period) | 0/34 (0%) | 3/34 (8.8%) | 22/34 (64.7%) |
| IXEQ4W_Re-Treatment (Randomized Withdrawal) Period | 0/33 (0%) | 0/33 (0%) | 11/33 (33.3%) |
| PBO (Post-Treatment Follow-Up) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| IXEQ4W (Post-Treatment Follow-Up) | 0/166 (0%) | 1/166 (0.6%) | 9/166 (5.4%) |
| ETN (Post-Treatment Follow-Up) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | PBO (Double-Blinded Treatment Period) | IXEQ4W (Double-Blinded Treatment Period) | ETN (Double-Blinded Treatment Period) | PBO/IXEQ4W (Maintenance Period) | IXEQ4W/IXEQ4W (Maintenance Period) | ETN/IXEQ4W (Maintenance Period) | PBO/IXEQ4W/IXEQ4W (Extension Period) | IXEQ4W/IXEQ4W/IXEQ4W (Extension Period) | ETN/IXEQ4W/IXEQ4W (Extension Period) | PBO (Randomized Withdrawal Period) | IXEQ4W (Randomized Withdrawal Period) | IXEQ4W_Re-Treatment (Randomized Withdrawal) Period | PBO (Post-Treatment Follow-Up) | IXEQ4W (Post-Treatment Follow-Up) | ETN (Post-Treatment Follow-Up) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Herpes zoster oticusInfections and infestations | 0/56 | 0/115 | 0/30 | 0/53 | 0/113 | 1/28 | 0/34 | 0/68 | 0/9 | 0/33 | 0/34 | 0/33 | 0/6 | 0/166 | 0/2 |
| OverdoseInjury, poisoning and procedural complications | 0/56 | 0/115 | 1/30 | 0/53 | 0/113 | 0/28 | 0/34 | 0/68 | 0/9 | 0/33 | 0/34 | 0/33 | 0/6 | 0/166 | 0/2 |
| FuruncleInfections and infestations | 0/56 | 0/115 | 0/30 | 0/53 | 0/113 | 0/28 | 0/34 | 0/68 | 0/9 | 0/33 | 1/34 | 0/33 | 0/6 | 0/166 | 0/2 |
| AstrocytomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/56 | 0/115 | 0/30 | 0/53 | 0/113 | 0/28 | 0/34 | 0/68 | 0/9 | 0/33 | 1/34 | 0/33 | 0/6 | 0/166 | 0/2 |
| EpilepsyNervous system disorders | 0/56 | 0/115 | 0/30 | 0/53 | 0/113 | 0/28 | 0/34 | 0/68 | 0/9 | 0/33 | 1/34 | 0/33 | 0/6 | 0/166 | 0/2 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/36 | 0/63 | 0/18 | 1/35 | 0/61 | 0/17 | 0/22 | 0/37 | 0/3 | 0/17 | 0/23 | 0/19 | 0/2 | 0/104 | 0/1 |
| Inflammatory bowel diseaseGastrointestinal disorders | 0/56 | 0/115 | 0/30 | 1/53 | 0/113 | 0/28 | 0/34 | 0/68 | 0/9 | 0/33 | 0/34 | 0/33 | 0/6 | 0/166 | 0/2 |
| TonsillitisInfections and infestations | 0/56 | 0/115 | 0/30 | 1/53 | 0/113 | 0/28 | 0/34 | 0/68 | 0/9 | 0/33 | 0/34 | 0/33 | 0/6 | 0/166 | 0/2 |
| Crohn's diseaseGastrointestinal disorders | 0/56 | 0/115 | 0/30 | 0/53 | 2/113 | 0/28 | 0/34 | 0/68 | 0/9 | 0/33 | 0/34 | 0/33 | 0/6 | 1/166 | 0/2 |
| DehydrationMetabolism and nutrition disorders | 0/56 | 0/115 | 0/30 | 0/53 | 2/113 | 0/28 | 0/34 | 0/68 | 0/9 | 0/33 | 0/34 | 0/33 | 0/6 | 0/166 | 0/2 |
| Event | PBO (Double-Blinded Treatment Period) | IXEQ4W (Double-Blinded Treatment Period) | ETN (Double-Blinded Treatment Period) | PBO/IXEQ4W (Maintenance Period) | IXEQ4W/IXEQ4W (Maintenance Period) | ETN/IXEQ4W (Maintenance Period) | PBO/IXEQ4W/IXEQ4W (Extension Period) | IXEQ4W/IXEQ4W/IXEQ4W (Extension Period) | ETN/IXEQ4W/IXEQ4W (Extension Period) | PBO (Randomized Withdrawal Period) | IXEQ4W (Randomized Withdrawal Period) | IXEQ4W_Re-Treatment (Randomized Withdrawal) Period | PBO (Post-Treatment Follow-Up) | IXEQ4W (Post-Treatment Follow-Up) | ETN (Post-Treatment Follow-Up) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/56 | 13/115 | 0/30 | 7/53 | 16/113 | 4/28 | 0/34 | 8/68 | 0/9 | 4/33 | 11/34 | 2/33 | 0/6 | 1/166 | 0/2 |
| Upper respiratory tract infectionInfections and infestations | 4/56 | 6/115 | 0/30 | 5/53 | 13/113 | 2/28 | 10/34 | 11/68 | 0/9 | 3/33 | 1/34 | 2/33 | 0/6 | 0/166 | 0/2 |
| Injection site reactionGeneral disorders | 0/56 | 11/115 | 0/30 | 8/53 | 20/113 | 0/28 | 0/34 | 2/68 | 0/9 | 0/33 | 0/34 | 1/33 | 0/6 | 0/166 | 0/2 |
| BronchitisInfections and infestations | 0/56 | 0/115 | 1/30 | 1/53 | 0/113 | 1/28 | 3/34 | 1/68 | 0/9 | 0/33 | 0/34 | 0/33 | 1/6 | 0/166 | 0/2 |
| CellulitisInfections and infestations | 1/56 | 0/115 | 0/30 | 0/53 | 0/113 | 0/28 | 0/34 | 0/68 | 0/9 | 0/33 | 0/34 | 0/33 | 1/6 | 0/166 | 0/2 |
| Gastroenteritis viralInfections and infestations | 0/56 | 0/115 | 0/30 | 0/53 | 4/113 | 2/28 | 0/34 | 0/68 | 0/9 | 0/33 | 0/34 | 0/33 | 1/6 | 0/166 | 0/2 |
| PharyngitisInfections and infestations | 0/56 | 2/115 | 2/30 | 2/53 | 8/113 | 4/28 | 3/34 | 2/68 | 1/9 | 2/33 | 1/34 | 2/33 | 0/6 | 0/166 | 0/2 |
| TonsillitisInfections and infestations | 2/56 | 1/115 | 0/30 | 1/53 | 5/113 | 4/28 | 1/34 | 4/68 | 0/9 | 1/33 | 3/34 | 2/33 | 0/6 | 0/166 | 0/2 |
| Irritable bowel syndromeGastrointestinal disorders | 0/56 | 0/115 | 0/30 | 0/53 | 0/113 | 0/28 | 0/34 | 0/68 | 1/9 | 0/33 | 0/34 | 1/33 | 0/6 | 0/166 | 0/2 |
| InfluenzaInfections and infestations | 0/56 | 2/115 | 2/30 | 1/53 | 4/113 | 0/28 | 1/34 | 4/68 | 1/9 | 0/33 | 1/34 | 0/33 | 0/6 | 1/166 | 0/2 |
| Age, Continuous(years) | Placebo | Ixekizumab | Open-label Etanercept | Total |
|---|---|---|---|---|
| Mean | 13.1 ± 2.79 | 13.7 ± 3.14 | 13.7 ± 2.95 | 13.5 ± 3.02 |
| Sex: Female, Male(Participants) | Placebo | Ixekizumab | Open-label Etanercept | Total |
|---|---|---|---|---|
| Female | 36 | 63 | 18 | 117 |
| Male | 20 | 52 | 12 | 84 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ixekizumab | Open-label Etanercept | Total |
|---|---|---|---|---|
| Hispanic or Latino | 11 | 30 | 7 | 48 |
| Not Hispanic or Latino | 42 | 82 | 23 | 147 |
| Unknown or Not Reported | 3 | 3 | 0 | 6 |
| Race (NIH/OMB)(Participants) | Placebo | Ixekizumab | Open-label Etanercept | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 1 | 3 |
| Asian | 2 | 4 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 0 | 6 |
| White | 45 | 95 | 25 | 165 |
| More than one race | 3 | 10 | 3 | 16 |
| Unknown or Not Reported | 3 | 1 | 1 | 5 |
| Region of Enrollment(Participants) | Placebo | Ixekizumab | Open-label Etanercept | Total |
|---|---|---|---|---|
| Puerto Rico | 3 | 5 | 0 | 8 |
| Argentina | 3 | 7 | 3 | 13 |
| Hungary | 6 | 13 | 2 | 21 |
| United States | 22 | 42 | 0 | 64 |
| Czechia | 2 | 6 | 4 | 12 |
| Spain | 5 | 4 | 3 | 12 |
| Russia | 4 | 7 | 4 | 15 |
| Canada | 1 | 6 | 0 | 7 |
| Netherlands | 0 | 1 | 0 | 1 |
| Poland | 5 | 12 | 8 | 25 |
| Mexico | 1 | 4 | 2 | 7 |
| France | 1 | 1 | 1 | 3 |
| Germany | 3 | 7 | 3 | 13 |
| Psoriasis Area Severity Index (PASI)(Score on a scale) | Placebo | Ixekizumab | Open-label Etanercept | Total |
|---|---|---|---|---|
| Mean | 19.73 ± 8.010 | 19.75 ± 7.509 | 24.78 ± 7.448 | 20.49 ± 7.81 |
| (sPGA)(Score on a scale) | Placebo | Ixekizumab | Open-label Etanercept | Total |
|---|---|---|---|---|
| Mean | 3.5 ± 0.63 | 3.6 ± 0.61 | 4.1 ± 0.31 | 3.63 ± 0.61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2017 to primary completion in Feb 2019, 22 months.
Results were first posted in Mar 2020, 1 year 1 month after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 22 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ixekizumab · Etanercept